Hat tip to Kaz YMB

[biopearl123]

Special thanks to Kaz for the dig on YMB. It is interesting to speculate about the potential relationships that could develop or already have with Geron’s co sponsors of these seminars.

[kmall]

Every once and a while, between all of the noise, a YMB poster pulls an excellent dig. This was definitely one of those. Thanks again for the Intel Kaz!! -Kmall

[LWS]

"As previously announced, Yahoo Finance's Conversations message board is being upgraded to provide a better experience. Comments are now temporarily available only in a read-only format. You will be able to post new comments as soon as the upgrade process is complete."

I agree that there are occasionally some worthwhile posts on the YMB. Since the YMB is being "upgraded", I could not find any reference to what you mentioned. Please supply some details. ---Thanks

[rccola335]

AN EXPERT DISCUSSION ON MYELODYSPLASTIC SYNDROMES: CURRENT AND FUTURE PERSONALIZED MANAGEMENT APPROACHES

This program is supported by educational grants from Bristol Myers Squibb; Geron Corporation; Karyopharm Therapeutics Inc.; and Novartis Pharmaceuticals Corporation

Dec 9, 2022: 11:00 a.m. - 2:00 p.m. Central time
Sheraton New Orleans
Napoleon B 1-3 + Corridor A/B

New innovations have changed clinical practice in the management of myelodysplastic syndromes (MDS) and this interactive symposium will focus on evolving therapeutic standards and emerging therapeutic options with expert faculty providing practical insights for disease and supportive care management of MDS across the spectrum of low- to high-risk disease and following HMA failure. Using different case presentations, the experts will discuss key clinical questions, available supporting evidence, and challenges that affect therapeutic decisions as well as their individual treatment recommendations for each case. Throughout the symposium, the audience will be able to vote on case scenarios and directly text questions regarding their specific challenges to the panel for their consideration. Discussion topics will include:
Risk stratification in MDS
Managing anemia in very low–risk, low-risk, or intermediate-risk MDS
Novel therapeutic approaches for the treatment of lower-risk MDS
Latest guidance on the treatment of higher-risk MDS and managing relapsed/refractory MDS
CHAIR:

Rami S. Komrokji
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

SPEAKERS:

María Diez-Campelo, MD, PhD
University Hospital of Salamanca
Salamanca, Spain

Amer M. Zeidan, MD
Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center
New Haven, CT

-----

Friday Satellite Symposia

FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company. The 2022 FSS will take place on Friday, December 9, 2022.

[kmall]

Bp - Hopefully one thing that we won't have to speculate about is manufacturing issues of Imetelstat with any "special relationships" of co-sponsors which may arise at these seminars. Remember that the Oligonucleotide facility in Banwol, Korea passed FDA PAI with flying colors back in August........

http://www.koreabiomed.com/news/article ... dxno=14300

Perhaps they took into consideration the $74B Bristol Meyers/Celgene deal which caused a bit of a concern for BMY.........

https://www.fiercepharma.com/pharma/bri ... g-concerns

Sure am glad they checked that one off the list. -Kmall

[biopearl123]

No question. One particle of dust in the wrong place and you are screwed. The FDA shows no mercy. We have seen it many times and Geron and their manufacturing team knows the importance of “immaculate production” and the inevitable delays that would follow failure to achieve perfection in manufacturing. bp